Compare
Zoetis Inc. vs Vertex Pharmaceuticals Inc vs Viatris Inc vs Organon & Co.
| Latest fiscal year | Zoetis Inc. ZTS | Vertex Pharmaceuticals Inc VRTX | Viatris Inc VTRS | Organon & Co. OGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.47B | $12.00B | $14.30B | $6.22B |
| Revenue growth (YoY) | +2.3% | +8.9% | -3.0% | -2.9% |
| Gross margin | 71.8% (computed) | 86.2% (computed) | 35.1% | 53.3% |
| Operating margin | n/a | 34.8% | -18.6% | n/a |
| Net margin | 28.2% | 32.9% | -24.6% | 3.0% |
| Net income | $2.67B | $3.95B | -$3.51B | $187.00M |
| EPS (Diluted) | $6.02 | $15.32 | -$3.00 | $0.72 |
| Operating cash flow | $2.90B | $3.63B | $2.32B | $700.00M |
| Free cash flow | $2.28B | $3.19B | $1.94B | $538.00M |
| Cash & equivalents | n/a | $5.08B | $1.32B | $574.00M |
| Total assets | $15.47B | $25.64B | $37.19B | $12.87B |
| Total liabilities | $12.14B | $6.98B | $22.48B | $12.12B |
| Shareholders' equity | $3.33B | $18.67B | $14.71B | $752.00M |
| Return on year-end equity | 80.2% | 21.2% | -23.9% | 24.9% |
| Shares outstanding | 424.93M | 253.99M | n/a | 260.32M |
Revenue, most recent five fiscal years
| Fiscal year | Zoetis Inc. | Vertex Pharmaceuticals Inc | Viatris Inc | Organon & Co. |
|---|---|---|---|---|
| Latest | $9.47B Ended 2025-12-31 | $12.00B Ended 2025-12-31 | $14.30B Ended 2025-12-31 | $6.22B Ended 2025-12-31 |
| 1 year earlier | $9.26B Ended 2024-12-31 | $11.02B Ended 2024-12-31 | $14.74B Ended 2024-12-31 | $6.40B Ended 2024-12-31 |
| 2 years earlier | $8.54B Ended 2023-12-31 | $9.87B Ended 2023-12-31 | $15.43B Ended 2023-12-31 | $6.26B Ended 2023-12-31 |
| 3 years earlier | $8.08B Ended 2022-12-31 | $8.93B Ended 2022-12-31 | $16.26B Ended 2022-12-31 | $6.17B Ended 2022-12-31 |
| 4 years earlier | $7.78B Ended 2021-12-31 | $7.57B Ended 2021-12-31 | $17.89B Ended 2021-12-31 | $6.30B Ended 2021-12-31 |